“Towards Ending the Neglect?” DNDi Releases Update on its Paediatric HIV Programme
“Towards Ending the Neglect?” DNDi Releases Update on its Paediatric HIV Programme
[July 2016] As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing “4-in-1” fixed-dose combinations using the World Health Organization (WHO) recommended treat­ment regimen for infants and young chil­dren. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).
“Towards Ending the Neglect?” DNDi Releases Update on its Paediatric HIV Programme
The global response to AMR must not fail to address the needs of neglected patients
The global response to AMR must not fail to address the needs of neglected patients
Manica BalasegaramManica Balasegaram, Director, Global Antiobiotic Research and Development Partnership [June 2016] Far from being an apocalyptic fantasy, a post-antibiotic era in which common infections and minor injuries can kill has become a very real possibility. Of late, media headlines about ‘the end of the road’ for antibiotics have been plentiful. The latest case in May this year to receive a good deal of attention was of a patient in the US found to be carrying bacteria resistant to antibiotics of last resort. [Español] [Português]
The global response to AMR must not fail to address the needs of neglected patients
AusTrade supports Epichem leishmaniasis research programme
AusTrade supports Epichem leishmaniasis research programme
DNDi and its partner Epichem are pleased to announce that the Australian Tropical Medicine Commercialisation Grants Programme (ATMCG), with the support of Australia’s Trade and Investment Ministry (AusTrade), are providing $250,000 for a project which is focused on developing new treatments for leishmaniasis. The name of the project is: “Novel compounds for the treatment of Leishmaniasis in humans and animals,” which will be led by PharmAust Limited’s (ASX:PAA) subsidiary Epichem in partnership with DNDi.
AusTrade supports Epichem leishmaniasis research programme
DNDi delivers statement about CEWG on R&D Financing and Coordination at 69th World Health Assembly
DNDi delivers statement about CEWG on R&D Financing and Coordination at 69th World Health Assembly
At the 69th WHA, Member States were asked to consider the outcomes of the Open-Ended Meeting and continue discussions on issues related to monitoring, coordination and financing for health research. Michelle Childs, DNDi‘s Head of Policy Advocacy, delivered the following statement on behalf of DNDi.
DNDi delivers statement about CEWG on R&D Financing and Coordination at 69th World Health Assembly
See all news

Scientific Articles

See all scientific articles

Events

  • AIDS 2016

    21st International AIDS Conference

    July 18 - 22, 2016 Durban, South Africa DNDi, CHAI, UNITAID, and NEPHAK held an AIDS 2016 Satellite Session to share practical and programmatic experience developing and introducing new paediatric ARV formulations.
  • The 7th APS International PharmSci 2016

    Pharmaceutical Sciences: Improving World Health

    September 5-7, 2016 Glasgow, Scotland Steve Robinson, Head of Pharmaceutical Development at DNDi, will present on neglected diseases.
  • XIX International Congress of Tropical Medicine and Malaria

    ICTMM

    September 18 - 22, 2016 Brisbane, Australia Robert Don, Discovery & Preclinical Director, DNDi and Eduard Ziljstra, Senior Consultant, DNDi will be speaking at this event.
See all events